A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma.

Authors :: Baramidze, Ana
Gogishvili, Miranda
Makharadze, Tamta
Zhvania, Mariam
Vacharadze, Khatuna
Crown, John
Melkadze, Tamar
Hamid, Omid
Long, Georgina V.
Robert, Caroline
Sznol, Mario
Martinez-Said, Hector
Mani, Jayakumar
Chaudhry, Usman
Salvati, Mark
Lowy, Israel
Fury, Matthew G.
Gullo, Giuseppe
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS9602-TPS9602, 1p
Publication Year :: 2023

Full Text Access

Tools